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Melanoma Inhibitor of Apoptosis Protein (ML-IAP)
Specific Cytotoxic T Lymphocytes Cross-React with
an Epitope from the Auto-Antigen SS56
Rikke Bæk Sørensen1, Mikkel Faurschou2, Lone Troelsen2, David Schrama3, Søren Jacobsen2,
Ju¨rgen C. Becker3, Per thor Straten1 and Mads Hald Andersen1
A large proportion of melanoma patients host a spontaneous T-cell response specifically against ML-IAP-derived
peptides. In this study, we describe that some ML-IAP-specific cytotoxic T cells isolated from melanoma patients
cross react with an epitope from the auto-antigen SS56. SS56 is a recently described target of autoantibody
responses in Sjo¨gren’s syndrome (SS) as well as systemic lupus erythematosus (SLE). Here, we describe that
SS56 is also an auto-antigen for T cells in SS and SLE. Hence, SS56-specific T cells could readily be detected in
circulation and among the infiltrating cells of SLE skin lesions. SS56-specific T cells were able to lyse target cells
presenting the peptide epitope on the surface. Notably, SS56-specific CD8 T cells isolated from an SS patient
cross reacted with the ML-IAP epitope. This early evidence of a target for auto-reactive CTL in SS and SLE
patients; it is to our knowledge previously unreported and underscores the important role of CD8 T cells in
autoimmune disorders. Furthermore, the cross-reactivity against the auto-antigen SS56 and the tumor-antigen
ML-IAP confirms the link between autoimmunity and anti-cancer cellular immune responses.
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INTRODUCTION
A finely orchestrated balance between activating and
inhibitory signals is fundamental for the ability of the immune
system to effectively attack and eliminate pathogenic
microbes without reacting against self-antigens. Derange-
ments of this balance underlie the pathogenesis of auto-
immune diseases (Blanco et al., 2005b). The majority of
research into the biology of autoimmune diseases has—
historically—focused on B-lymphocytes and CD4 T-helper
cells. However, recent technical advances as well as an
improved understanding of the regulatory role have brought
more attention to CD8 T cells (Yasuoka et al., 2004; Sospedra
and Martin, 2005; Andersen et al., 2006). It was recently
reported that a high proportion of activated CD8 T cells could
be found in the blood of systemic lupus erythematosus (SLE)
patients (Blanco et al., 2005a). Furthermore, CD8 T cells
infiltrate the periglomerular area in patients with severe lupus
nephritis and are linked to a poor outcome after induction
therapy (Couzi et al., 2007).
The close association between tumor immunity and auto
immunity is underlined by many observations, for example,
the association between onset of vitiligo and better outcome
of melanoma (Bystryn et al., 1987), as well as the correlation
between autoimmunity and survival during treatment of
melanoma patients with interferon-a (Gogas et al., 2006). In
addition, treatment with anti-CTLA-4 antibodies can induce
durable objective clinical responses in melanoma and renal
cell carcinoma patients, who are directly correlated with
immune-related adverse events (Beck et al., 2006; Kaufman
and Wolchok, 2006; Downey et al., 2007). Conversely,
increased knowledge on the parameters that control and
inhibit immune responses may provide strategies for enhance-
ment of the efficacy of anti-cancer immunotherapy. Hence,
tolerance to tumor antigens can be mediated through the same
mechanisms that induce T-cell tolerance to normal self-
antigens to avoid autoimmunity (Yan and Mamula, 2002).
Melanoma inhibitor of apoptosis protein (ML-IAP, also
named livin) is a critical cellular factor as increased
expression levels confer resistance to apoptotic stimuli,
thereby contributing to the pathogenesis and progression of
melanoma (Kasof and Gomes, 2001; Nachmias et al., 2003).
The majority of melanoma cell lines as well as melanoma
cultures from primary melanoma patients express high levels
of ML-IAP in contrast to primary melanocytes. We and others
have identified peptide-epitopes derived from ML-IAP, which
are recognized by circulating cytotoxic T lymphocytes (CTL)
obtained from melanoma patients (Schmollinger et al., 2003;
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Andersen et al., 2004a, b). Surprisingly, we also identified a
T-cell response against an HLA-A2-restricted peptide ML-
IAP280289 (QLCPICRAPV) in a few control donors (Andersen
et al., 2004b). Consequently, we examined if any homolog
peptides were present in other human proteins, particularly
those associated with autoimmune diseases. To this end, we
identified a highly homologous peptide from the protein SS56
(SS565564 (YTCPLCRAPV)); SS56 is a recently described
cellular target of antibody responses in Sjo¨gren’s syndrome
(SS) and SLE (Billaut-Mulot et al., 2001). The major target
organs of SS are lacrimal glands and salivary glands where
prominent lymphocytic infiltration occurs. Extraglandular
manifestations and varying levels of organ-unspecific auto-
antibody production indicate the systemic nature of this
disease (Nakamura et al., 2006). SLE is also a systemic
autoimmune disease predominantly affecting women, with a
wide range of clinical features and a prognosis that may range
from benign to fatal, primarily depending on the extent and
severity of internal organ involvement such as nephritis and
central nervous system involvement (Cook and Botto, 2006;
D’Cruz et al., 2007).
The purpose of this study was to investigate whether SS56
is a target for CD8 T cells in primary SS (pSS) and SLE.
Furthermore, we examined if cytotoxic T cells cross-react
between SS56 and ML-IAP.
RESULTS
ML-IAP280289-specific T cells cross react with SS565564
ML-IAP280289-specific T-cell cultures were established using
peripheral blood lymphocytes (PBL) from a melanoma patient
harboring a spontaneous T-cell response against the peptide
as identified by ELISPOT assay (Andersen et al., 2004b). PBL
from this melanoma patient were stimulated four times
in vitro with ML-IAP280289-pulsed autologous dendritic
cells. The T-cell culture was examined for recognition of
ML-IAP280289 as well as SS565564 by IFN-g ELSPOT assay.
A strong T-cell response was observed against ML-IAP280289,
as well as a minor response against SS565564 (Figure 1a).
Next, CTL clones were established from the ML-IAP28028-
specific bulk culture by limiting dilution. After a short
expansion step, the specificity of the growing clones was
analyzed in standard 51Cr-release assays. Hence, a panel of
the ML-IAP280289-specific T-cell clones were examined for
recognition of ML-IAP280289 as well as SS565564 using
peptide-pulsed T2-cells as target cells. Whereas some clones
only recognized the ML-IAP280289 peptide, other clones in
addition lysed T2-cells pulsed with the SS565564 peptide
(Figure 1b). Next, we examined the T-cell avidity of the cross-
reactive clones against ML-IAP280289 as well as SS565564.
T-cell avidity can be defined as the lowest amount of peptide
needed for the activation of the T cells. We found that the
amount of peptide needed for activation was lower for ML-
IAP280289 compared to that of SS565564 (Figure 1c).
FACS analyses of SS56-specific T cells
The spontaneous occurrence of SS565564-specific CTL in
PBL from pSS and SLE patients was evaluated using FACS
analyses and HLA-A2/SS565564 dextramer staining. These
data confirmed that SS565564-specific CD8 T cells are
present in the blood of HLA-A2 pSS patients and SLE patients
(Figure 2). Figure 2a illustrates an example of a T-cell
response in a pSS and an SLE patient with a HLA-A2/HIV-1
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Figure 1. ML-IAP280289-specific T cells recognize SS565564. (a) Specificity of an ML-IAP280289-specific T-cell culture measured in an IFN-g ELISPOT
assay. T cells were plated at 104 cells per well in duplicates either without peptide or with ML-IAP280289 or SS565564 peptide. (b) Specificity of five
ML-IAP280289-specific T-cell clones assayed by
51Cr-release assays measuring cell lysis of T2 cells without peptide or pulsed with ML-IAP280289 or SS565564
peptide (E/T ratio¼ 15:1). (c) Peptide affinity of two ML-IAP280289-specific T-cell clones assayed by 51Cr-release assays measuring cell lysis of T2 cells
pulsed with different concentrations of the ML-IAP280289 or SS565564 peptide (E/T ratio¼ 10:1).
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pol476484 dextramer used as control. PBL from eight HLA-
A2-positive healthy individuals, seven HLA-A2-positive
patients with pSS, and 10 patients with SLE were analyzed.
This analysis revealed an average frequency of SS56-specific
cells of around 0.01% of the CD8 cells in PBL from pSS and
SLE patients (Figure 2b), with a maximum of 0.03% in one
pSS patient and two SLE patients. As negative controls we
included HLA-A2-negative pSS and SLE patients. No specific
cells could be detected in any of these patients (Figure 2b).
Detection of SS56 reactive T cells in active SLE skin lesions
The prognostic and clinical significance of measuring specific
T cells in peripheral blood has been questioned repeatedly
(thor Straten et al., 1999). Thus, we also tested for the
presence of HLA-A2/SS565564 reactive CD8 T lymphocytes
among infiltrating lymphocytes in inflammatory skin
lesions of SLE patients by means of HLA/peptide dextramer
staining. FITC-conjugated HLA-A2/ SS565564 dextramers
were used to stain acetone-fixed, frozen material as described
previously (Andersen et al., 2001b; Schrama et al., 2002),
and antigen-specific cells were visualized using a confocal
laser microscope. Sections of cutaneous SLE manifestations
from 10 HLA-A2-positive and 10 HLA-A2-negative
SLE patients were analyzed. This analysis revealed the
in situ presence of SS565564-reactive, CD8 CTL in two of
the HLAA2-positive, but none of the HLA-A2-negative
patients (Figure 3). Tissue samples obtained from HLA-A2-
positive patients suffering from allergic contact dermatitis
and atopic eczema served as controls; in none of these
lesions could SS565564-reactive, CD8 CTL be detected. It
should be noted, that only the CD8/multimer double-positive
cells were regarded as a positive signal—not specific
staining of collagen fibers by FITC, which is a well known
problem; the difference in morphology between collagen
and cells is a valid tool to distinguish them from each
other.
Functional T-cell responses against the SS56-derived peptide in
PBL from patients with pSS, SLE patients, and healthy
individuals
By means of the ELISPOT assay, we further examined
peripheral blood T cells from HLA-A2 patients with pSS
102
103
104
102 103 104 105
105 HIV HIV
SS56 SS56
CD
8 
AP
C-
A
MHC dextramer PE-A
102
103
104
102 103 104 105
105
CD
8 
AP
C-
A
MHC dextramer PE-A
102
103
104
102 103 104 105
105
CD
8 
AP
C-
A
MHC dextramer PE-A
102
103
104
102 103 104 105
105
CD
8 
AP
C-
A
MHC dextramer PE-A
0.04
0.035
0.03
0.025
0.02
0.015
0.01
0.005
0
HIV SS56
Healthy (n=8) pSS (n=7)
HIV SS56 HIV SS56 HIV SS56
HLA-A2-
negative patients
(n=3)
SLE (n =10)
Fr
e
qu
en
cy
 o
f d
ex
tra
m
e
r-
po
sit
ive
 c
e
lls
 o
f C
D8
 T
 c
el
ls
Figure 2. Detection of SS56 specific CD8 T cells in peripheral blood from
patients with pSS and SLE. (a) Example of SS565564-specific CD8 T cells in
PBL from a patient with pSS (left) and a patient with SLE (right) visualized by
flow cytometry using the dextramer complex HLA-A2/ SS565564-PE, and
CD8-allophycocyanin. As a negative control, PBL from the same patients
were stained with the dextramer complex HLA-A2/HIV pol476–484-PE, and
CD8-allophycocyanin. (b) The frequency of HIV-1 pol476484 and SS565564
dextramer-positive CD8 T cells in PBL from eight HLA-A2-positive healthy
individuals, seven HLA-A2-positive patients with pSS, 10 HLA-A2-positive
patients with SLE and three HLA-A2-negative patients.
Figure 3. In situ detection of SS56-reactive CTL. Confocal laser scanning
microscopy was used to detect the presence of CTL reacting with a Cy3-
conjugated anti-CD8 antibody (red channel) and an FITC-conjugated
multimeric HLA-A2/ SS565564 construct (green channel) in skin lesions from
HLA-A2-positive and HLA-A2-negative SLE patients. Double positive cells
appear yellow. HLA-A2/SS565564-reactive CD8 T cells were detected in 2
out of 10 HLA-A2 patients. Two respective areas of these tissue samples are
depicted; a and b derived from one, c and d from the other patient.
Magnification a, 400 ; b–d 600 . The scale bar represents 25 mm.
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(n¼8) and SLE (n¼ 11), as well as healthy individuals
(n¼11) for SS565564 peptide-specific IFN-g production. This
method was previously demonstrated to be highly effective
for identifying antigen-specific CTL in cancer patients (Herr
et al., 1999; Andersen et al., 2001a; Scheibenbogen et al.,
2002). PBL were stimulated once with peptide in vitro before
examination by ELISPOT. This procedure was chosen to
extend the sensitivity of the ELISPOT as described (Andersen
et al., 2001a; Keilholz et al., 2002). Using this approach, we
were able to identify more than 50 SS565564-specific T cells/
2105 PBL in five pSS-patients and three SLE patients
(Figure 4). To further characterize the functional capacity of
SS56-reactive CTL, these cells were isolated from PBL from a
pSS patient by FACS using HLA-A2/ SS565564 dextramer
complexes. After expansion using phytohemagglutinin, IL-2,
and feeder cells, we examined the lytic capacity of these cells
by chrome release assay. This revealed that SS56-specific T
cells indeed killed SS565564 loaded T2 cells. In addition,
these isolated SS565564-reactive T cells lysed ML-IAP280289
loaded T2 cells, demonstrating the cross-reactivity of the T
cells (Figure 5).
Clonotypes of SS565564- and ML-IAP280289-isolated T cells
To extend this observation, we directly isolated both
SS565564-and ML-IAP280289-specific T cells from the same
pSS patient by means of FACS to analyze them ex vivo
(Figure 6a). In this respect, 98 SS565564 and 114
ML-IAP280289-specific T cells isolated from 5106 PBL
were subjected to RT-PCR/denaturing gradient gel electro-
phoresis-based TCR clonotype mapping. Two T-cell clones
were detected among the SS565564-specific T cells (BV1 and
BV4). Notably, one of these clones (BV4) was also present
among the ML-IAP280289 reactive T cells; confirming that
part of the SS565564 T cells cross react with the ML-
IAP280289 peptide (Figure 6b). The identity of the BV4 CDR3
regions was verified by sequencing (Figure 6c).
DISCUSSION
We recently described natural cellular immune responses
against the inhibitor of apoptosis protein ML-IAP in melano-
ma patients. Thus, circulating cytotoxic T cells obtained from
melanoma patients recognized an HLA-A2-restricted peptide
ML-IAP280289 (QLCPICRAPV). However, this response could
also be detected in a small fraction of normal donors
(Andersen et al., 2004b). T-cell receptors (TCR) recognize
peptides complexed to HLA-molecules. Recognition of
peptide/HLA ligands by the TCR is highly peptide specific,
as minor variations in a T-cell epitope can completely change
their capacity to induce T-cell activation. However, certain
TCR can also recognize sequence-related and -unrelated
(‘‘mimicry’’) epitopes presented by homologous MHC mole-
cules. Hence, the TCR specificity repertoire is flexible in that
the TCR can interact productively not only with wild-type
peptide but also with slightly altered peptides (like partial
TCR agonists or TCR antagonists) in the context of HLA-
molecules (De Magistris et al., 1992; Geluk et al., 1997). This
flexibility in TCR-mediated recognition of various peptide/
MHC complexes may play a vital role in auto-immunity. The
repertoire of peptide variants recognized is TCR clonotype
dependent. ML-IAP280289 and SS565564 are almost iden-
tical peptides. Hence, we examined if the ML-IAP280289-
specific T cell cultures we had expanded from a melanoma
patient cross-reacted with the SS565564 peptide. We found
that in the polyclonal ML-IAP-specific bulk culture there was
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Figure 4. HLA-A2-restricted T-cell responses against SS56 as measured by
INF-c ELISPOT. PBL from 11 healthy individuals, eight patients with pSS, and
11 patients with SLE were analyzed. All individuals were HLA-A2 positive.
T lymphocytes were stimulated once with SS565564 (YTCPLCRAPV) before
being plated at 3105 cells per well in duplicates either without or with
peptide. The average number of peptide-specific spots (after subtraction of
spots without added peptide) was calculated for each patient using the
ImmunoSpot Series 2.0 Analyzer (CTL Analyzers, LLC, Cleveland).
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Figure 5. Cytolytic capacity of SS56-specific CTL. SS565564-reactive CTL
were isolated from PBL from a pSS patient by flow cytometry using HLA-A2/
SS565564 dextramers (a). The isolated cells were expanded for 12 days using
IL-2, phytohemagglutinin and a mix of irradiated lymphocytes from three
healthy donors. The culture were examined in a chrome release assay in
duplicates using either T2 cells without peptide, or pulsed with SS565564
peptide or ML-IAP280289 peptide as target cells (b). Effector/Target
ratio¼1:3, measurements were made in duplicates.
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in addition some reactivity against the slightly altered peptide
from SS56, indicating that it contained some T cells which
cross-reacted with the slightly altered peptide from SS56. This
was illustrated after cloning and expansion of specific cells,
as we obtained clones highly specific for the ML-IAP, as well
as cross-reactive clones. Peptide titration curves of the clones
illustrated that a lower amount of ML-IAP peptide was
needed for activation of the cross-reactive T cells compared
to the SS56 peptide. These findings lead us to scrutinize if the
SS565564 peptide were indeed an auto-antigen for T cells in
pSS and SLE. We describe that CTL responses against SS56
could readily be detected in blood and tissue samples
obtained from pSS and SLE patients by means of flow
cytometry and in situ detection assays using HLA-A2/
SS565564 dextramers. The infiltration of SS56-specific T
cells in situ suggests that these cells play a role in the
pathogenesis of these diseases. Moreover, the functional
capacity of the SS56-reactive cells was demonstrated by IFN-
g ELISPOT and cytotoxicity assays. It should be noted that the
inclusion of other cytokines, for example, TNF-a ELISPOT,
would have given a more precise description of the nature of
the SS56-specific immune response, the phenotype of the
specific cells, and would in addition have increased the
chances for detecting T-cell responses, as some specific cells
might release TNF-a and not IFN-g. However, due to ethical
reasons we were only allowed to draw a limited amount of
blood from each patient.
Interestingly, the ELISPOT data shows a bimodal distribu-
tion. SLE is characterized by a wide range of clinical features
and a prognosis that may range from benign to fatal. This
heterogeneity among patients could, however, not be
correlated with a CD8 response against SS56 in contrast to
anti-SS56 antibodies, which have been associated with
visceral complications in SLE (Billaut-Mulot et al., 2001).
However, it should be noted that when measuring HLA-
restricted CTL responses it is always difficult to compare
responders and non-responders. Hence, in patients without a
detectable response there might be a response against
another SS56 peptide restricted to the same or another
HLA-molecule.
The identification of a target for CD8 T cells, which to our
knowledge is previously unreported, may provide further
insight into the cellular and molecular mechanisms of
pathogenesis in two complex autoimmune diseases. Our
findings suggest a role of CD8 auto-antigen-specific T cells in
two diseases that have so far mainly been characterized by
the presence of specific auto-antibodies. Although many
studies have demonstrated a pivotal role of CD4 T cells in the
induction and maintenance of the immune response (Name-
kawa et al., 1995; Halse et al., 1996; Helsloot and Sturgess,
1997; Davies et al., 2002; Hoffman, 2004). The precise
nature of T cell–B cell interactions are still to be fully
delineated. In this regard, it would be very interesting to
examine the possible correlation between anti-SS56 CD4,
CD8 and antibody responses.
To further examine the cross reactivity between ML-IAP
and SS56 reactive T-cell cultures we showed that ML-
IAP280289-loaded target cells were lysed by SS565564-
specific T cells isolated from a pSS patient. In addition, we
directly isolated SS565564-specific T cells ex vivo by flow
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Figure 6. Clonotypes of SS565564- and ML-IAP280289-isolated T cells from a pSS patient. SS565564-specific T cells were isolated from PBL from a pSS
patient by means of FACS using HLA-A2/ SS565564 dextramers (a). The isolated cells were analyzed by the RT-PCR/denaturing gradient gel electrophoresis-
based TCR clonotype mapping. This technique allows the analysis for T-cell clonality in complex cell populations, even if only small number of cells are
available. As this method separates amplified TCR mRNA transcripts on the basis of the melting properties of the molecule, it is ideally suited for comparing
TCR sequences, as identical molecules will resolve at an identical position in the gel. This revealed that the isolated cells consisted of two clones (BV1 and BV4).
ML-IAP280289-specific cells were isolated from the same pSS patient using HLA-A2/ML-IAP280289 dextramers (a). The same BV4 clone could be detected
among these cells (b). The identity of the BV4 CDR3 regions was verified by sequencing (c).
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cytometry and the subsequent TCR clonotype analysis
revealed that these cells consisted of two clones. One of
these clones could be detected among the T cells isolated
from the same patient with the HLA-A2/ML-IAP280289
dextramer. Thus, SS565564-specific T cells in this pSS patient
cross reacts with the ML-IAP280289 peptide. The cross-
reactivity between an epitope from a tumor antigen and an
antigen involved in autoimmune disease accentuate the close
relationship between autoimmunity and anti-cancer re-
sponses. Obviously, the involvement of peptide-specific
CD8 T cells in SLE and pSS does not necessarily imply that
this is the case in all autoimmune disorders. However, it does
raise the question whether lessons could be learned regarding
anti-tumor immune responses by studying autoimmune
responses, in particular the mechanisms involved in regulat-
ing such responses. Counter-regulatory responses are im-
portant in the immune system; they help to limit the intensity
and extent of immune responses, which otherwise could
result in dangerous collateral damage to the host. However,
with regard to anti-cancer immunotherapy, counter-regula-
tory responses antagonize the ability to create an intense
immune response against the tumor. Moreover, this finding
raises the question of whether potential cross-reactivity
between a tumor antigen and other proteins should be
considered when antigens are chosen for anti-cancer
immunotherapy. This may be especially relevant when
choosing the specificity of TCR in case of adoptive transfer
with genetically modified lymphocytes as described in
several studies (Morgan et al., 2003, 2006; Kuball et al.,
2005, 2007).
Although it remains to be seen whether similar findings
with other tumor antigens are exceptions or the rule, it is
interesting to note that for quite a number of tumor antigens
responses have been detected in a low proportion of normal
donors. Renewed dialog between tumor immunologists,
oncologists, and rheumatologists is required to compare
and reconsider current models to delineate the similarities
and differences between tumor and auto-immunity.
MATERIALS AND METHODS
Patients
Peripheral blood lymphocytes were collected from 20 patients with
pSS and 20 patients with SLE from the Department of Rheumatology,
Rigshospitalet, Copenhagen, Denmark; eight patients with pSS and
11 SLE patients were HLA-A2 positive. Furthermore, skin biopsies
were obtained from 10 HLA-A2-positive and 10 HLA-A2-negative
SLE patients with LE skin lesions. All pSS patients met the
classification criteria for pSS (Vitali et al., 2002). The auto-antibody
status of the pSS patients was as follows: 18/20 positive for anti-SSA/
Ro, 13/20 positive for anti-SSB/La, 17/20 positive for anti-ANA og
18/20 positive for anti-IgM-RF. The SLE patients were diagnosed
according to the classification criteria for SLE (Tan et al., 1982). The
auto-antibody status of the SLE patients was as follows: 7/20 positive
for anti-SSA/Ro, 2/20 positive for anti-SSB/La, 17/20 positive for anti-
ANA og 12/20 positive for anti-DNA. The local Ethical Committee
(Copenhagen, Denmark) approval was received for the study
(number 01270846). The study is in accordance with the Helsinki
declaration. Written informed consent was obtained from all
participating patients. The study was also approved by the Danish
Data Protection Agency (number 2005-54-1783).
Establishment of ML-IAP280289 T-cell clones
PBL from a melanoma patient were stimulated with irradiated
autologous ML-IAP280289-loaded DC (PBL/DC ratio¼ 3 106:
3 105) with IL-7 (5 ngml1) and IL-12 (10 ngml1) (PeproTech,
London, UK). The cultures were restimulated ML-IAP280289-loaded
irradiated autologous DC (2 ) followed by ML-IAP280289-loaded
irradiated autologous PBL (3 ) and IL-2 (PeproTech, London, UK).
PBL from a ML-IAP280289-specific culture were cloned by limiting
dilution in the presence of a mix of irradiated lymphocytes from
three healthy donors ex vivowith 5% heat-inactivated human serum,
and IL-2 (PeproTech, London, UK). After expansion the clones were
tested for specificity and cytotoxic potential in a standard 51Cr-
release assay.
INF-c ELISPOT assay
To extend the sensitivity of the ELISPOT assay, PBL were stimulated
once in vitro prior to analysis (McCutcheon et al., 1997; Pass et al.,
1998). The ELISPOT assay was used to quantify peptide epitope-
specific INF-g releasing effector cells as described previously (Berke
et al., 2000). Briefly, nitrocellulose bottomed 96-well plates (Multi-
Screen MAIP N45, Millipore, Hedehusene, Denmark) were coated
with anti-IFN-g antibody (Mabtech, Nacka Strand, Sweden).
Stimulator T2 cells (with or without 10 mM peptide) and effector
cells at different concentrations were added. Unpulsed T2 cells and
T2 cells pulsed with HIV-1 pol476484 give similar responses in
ELISPOT as described (Meier et al., 2005). The following day,
biotinylated secondary antibody (Mabtech) were added, followed by
Avidin-enzyme conjugate (Mabtech) and finally the enzyme
substrate NBT/BCIP (Mabtech). The reaction was terminated by
washing with tap water on the appearance of dark purple spots. The
spots were counted using the ImmunoSpot Series 2.0 Analyzer (CTL
Analyzers, LLC, Cleveland) and the peptide-specific CTL frequency
could be calculated from the number of spot-forming cells. All
assays were performed in duplicate for each peptide antigen.
Fluorescence-activated cell sorting (FACS)
PBL was analyzed by flow cytometry using FACSAria (BD Biosciences,
Brøndby, Denmark). The T cells were stained with PE-conjugated
MHC-Dextramers (DAKO, Glostrup, Denmark), followed by antibody
staining with 7-AAD and the fluorochrome-couplet mAbs: CD8-APC
and CD3-FITC (BD Biosciences, Brondby, Denmark). Both stainings
were performed in RPMI-1640 media (GibcoBRL, Invitrogen, Taastrup,
Denmark), for 20minutes, 4 1C, in the dark. The MHC-Dextramer
complexes used were: HLA-A2/ SS565564 (YTCPLCRAPV), HLA-A2/
ML-IAP280289 (QLCPICRAPV) and as control HLA-A2/HIV-1
pol476484 (ILKEPVHGV). 100,000 CD8 cells were collected for each
patient. CD8/ SS565564 and CD8/ML-IAP280289-positive cells were
sorted for TCR clonotype mapping.
Immunohistochemistry stainings
Multimerized peptide/HLA complexes were used to identify antigen-
specific T cells in situ in lesions from SLE patients, as previously
described (Andersen et al., 2004b). The FITC-conjugated MHC-
Dextramer complexes used were: HLA-A2/ SS565564 (YTCPL-
CRAPV) and HLA-A2/ML-IAP280289 (QLCPICRAPV). Tissue sections
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were dried overnight and subsequently fixed in cold acetone for
5minutes. All incubation steps were performed in the dark at room
temperature: (a) Forty-five minutes of the primary antibody (1:100
diluted) (b) Cy 3-conjugated goat antimouse (1:500 diluted; code
115-165-100; Jackson ImmunoResearch, obtained from Dianova,
Hamburg, Germany) for forty-five minutes; and finally (c) the
multimers for 75minutes. Between each step, the slides were
washed two times for 10minutes in PBS/BSA 0.1%. The slides were
mounted in vectashield and kept in the refrigerator until observed
under the confocal microscope (Leica).
TCR clonotype mapping by denaturing gradient gel
electrophoresis
Denaturing gradient gel electrophoresis clonotype mapping of the
human TCR BV regions 1–24 has been described in detail (thor
Straten et al., 1998). Briefly, RNA was isolated using the Purescript
Isolation Kit (Gentra Systems Inc., Minneapolis, MN) and transcribed
cDNA was amplified by PCR using primers for the variable regions of
the TCR b chains in conjunction with a common constant region
primer.
Cytotoxicity assay
CD8/SS565564-specific cells were isolated and expanded shortly
using irradiated lymphocytes from three healthy donors with
phytohemagglutinin (Peprotech, London, UK) and IL-2 (Chiron,
Ratigen, Germany). The expanded T cells were analyzed using a
conventional 51Cr-release assay as described elsewhere (Andersen
et al., 1999). Target cells were peptide-pulsed, TAP-deficient T2 cells.
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